Faculty Collaboration Database

The effect of smoking on allogeneic transplant outcomes. Biol Blood Marrow Transplant 2009 Oct;15(10):1277-87

Date

09/15/2009

Pubmed ID

19747636

Pubmed Central ID

PMC2768519

DOI

10.1016/j.bbmt.2009.06.005

Scopus ID

2-s2.0-69749091932 (requires institutional sign-in at Scopus site)   25 Citations

Abstract

Using the Center for International Blood and Marrow Transplant Research (CIBMTR) data, we compared the transplant outcomes of patients with chronic myelogenous leukemia (CML) who were nonsmokers (NS) and past or current smokers (PCS). There were 2193 NS and 625 PCS who received matched sibling and unrelated donor allografts for CML in first chronic phase. We looked for dose effects and identified low and high dose smoking groups (>10 pack years, >1 pack per day). Outcomes were adjusted for known prognostic variables including the European Group for Blood and Marrow Transplant (EBMT) risk score. In multivariate analyses of sibling allograft recipients, relapse risk (RR) was higher (RR=1.67, P=.003) in smokers than NS, but the dose effects were not consistent. High-dose smokers experienced a 50% treatment-related mortality (TRM) versus 28% in the NS group at 5 years on univariate analysis, and the RR was 1.57 (P=.005) on multivariate analysis. Overall survival (OS) at 5 years was 68% in NS versus 62% in the low-dose smoking group versus 50% in the high-dose smoking group (P < .001). Smoking did not significantly affect outcomes in unrelated donor recipients, but numbers were smaller. High-dose smoking is associated with a reduction in OS in patients having sibling allografts for CML. A prospective study with detailed demographic, pulmonary function, and quality-of-life data would improve our understanding of this issue.

Author List

Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A, Burns LJ, Gupta V, Ho V, McCarthy PL, Ringdén O, Schouten HC, Seftel M, Rizzo JD

Authors

Brent R. Logan PhD Director, Professor in the Data Science Institute department at Medical College of Wisconsin
J. Douglas Rizzo MD, MS Director, Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Bone Marrow Transplantation
Disease-Free Survival
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Living Donors
Male
Middle Aged
Recurrence
Retrospective Studies
Risk Factors
Siblings
Smoking
Survival Rate
Transplantation, Homologous